Chronic kidney disease (CKD) has an increased risk of contracting tuberculosis (TB), with an incidence rate of 3,718 cases per 100,000 CKD patients. Standard four drugs (isoniazid, rifampin, pyrazinamide, and ethambutol) treatment are associated with side effects and poor adherence. Current guidelines provide comprehensive recommendations for managing TB in individuals with CKD. Pharmacokinetic studies of first-line anti-tubercular drugs in CKD are sparse, with most primarily focusing on patients on hemodialysis.
No takes yet. Share an insight, caveat, or question.
Datta et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: